European Commission clears UCB's acquisition of Schwarz

The European Commission has cleared the acquisition of Schwarz Pharma by UCB. While both companies are active in the research, development and commercialisation of pharmaceutical products, the Commission accepted that there were only a few markets in which both parties competed. Moreover, within these markets, the Commission recognised that the presence of established alternative suppliers would ensure that competition would continue to be strong. Mike Walker, Andrew Dick and Paul Reynolds of CRA International advised UCB throughout the transaction.

See Commission Press Release

< Back to news archive

Click here to print this page.Print this page